01 10Onglyza
02 7Onglyza/Kombiglyze XR/Komboglyze
03 1Onglyza/Kombiglyze Xr/Komboglyze
04 2Qtern
05 1Seloken
06 1Seloken /Toprol-XL
07 8Seloken/Toprol-XL
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 470
2019 Revenue in Millions : 527
Growth (%) : -11
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 821
2019 Revenue in Millions : 760
Growth (%) : 8
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 65
2019 Revenue in Millions : 70
Growth (%) : -7
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 951
2020 Revenue in Millions : 821
Growth (%) : 16
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 360
2020 Revenue in Millions : 470
Growth (%) : -23
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 52
2020 Revenue in Millions : 65
Growth (%) : -10
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 39
2021 Revenue in Millions : 52
Growth (%) : -25
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 257
2021 Revenue in Millions : 360
Growth (%) : -29
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 862
2021 Revenue in Millions : 951
Growth (%) : -9
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 640
2022 Revenue in Millions : 862
Growth (%) : -26
